CG Oncology (CGON) Cash & Equivalents (2023 - 2026)
CG Oncology's (CGON) quarterly Cash & Equivalents came in at $33.7 million in Q1 2026, down 18.74% YoY from $41.5 million in Q1 2025, and up 3.72% on a QoQ basis from $32.5 million in Q4 2025.
CG Oncology (CGON) Cash & Equivalents (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Cash & Equivalents data on file, last reported at $33.7 million in Q1 2026.
- Quarterly Cash & Equivalents fell 18.74% year-over-year to $33.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.7 million (down 18.74% YoY) and the FY2025 annual result came in at $32.5 million, down 87.36% from the prior year.
- Cash & Equivalents grew to $33.7 million in Q1 2026, from $32.5 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $257.1 million in Q4 2024 to a low of $8.3 million in Q4 2023.
- A 4-year average of $57.9 million and a median of $37.6 million in 2025 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2024 — Cash & Equivalents surged 3009.94% — and 2025, when it sank 87.36%.
- Tracing CGON's Cash & Equivalents over 4 years: stood at $8.3 million in 2023, then surged by 3009.94% to $257.1 million in 2024, then slumped by 87.36% to $32.5 million in 2025, then grew by 3.72% to $33.7 million in 2026.
- The last three Cash & Equivalents figures came in at $33.7 million (Q1 2026), $32.5 million (Q4 2025), and $45.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | 19.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.64 Mn |
| Mar 31, 2026 | 33.70 Mn |
| Dec 31, 2025 | 32.49 Mn |
| Sep 30, 2025 | 45.15 Mn |
| Jun 30, 2025 | 14.62 Mn |
| Mar 31, 2025 | 41.47 Mn |
| Dec 31, 2024 | 257.07 Mn |
| Sep 30, 2024 | 43.41 Mn |
| Jun 30, 2024 | 25.16 Mn |
| Mar 31, 2024 | 77.47 Mn |
| Dec 31, 2023 | 8.27 Mn |